Knuff & Co LLC Raises Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Knuff & Co LLC grew its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 2.3% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 34,310 shares of the biopharmaceutical company’s stock after acquiring an additional 770 shares during the period. Gilead Sciences comprises approximately 1.5% of Knuff & Co LLC’s portfolio, making the stock its 19th biggest holding. Knuff & Co LLC’s holdings in Gilead Sciences were worth $2,175,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of GILD. Cooper Financial Group grew its holdings in shares of Gilead Sciences by 4.3% during the 2nd quarter. Cooper Financial Group now owns 3,604 shares of the biopharmaceutical company’s stock worth $243,000 after purchasing an additional 149 shares in the last quarter. LeJeune Puetz Investment Counsel LLC grew its holdings in shares of Gilead Sciences by 0.6% during the third quarter. LeJeune Puetz Investment Counsel LLC now owns 26,385 shares of the biopharmaceutical company’s stock valued at $1,672,000 after buying an additional 155 shares during the last quarter. Alpha Cubed Investments LLC grew its holdings in shares of Gilead Sciences by 0.6% during the second quarter. Alpha Cubed Investments LLC now owns 25,592 shares of the biopharmaceutical company’s stock valued at $1,729,000 after buying an additional 156 shares during the last quarter. Blume Capital Management Inc. grew its holdings in shares of Gilead Sciences by 4.8% during the second quarter. Blume Capital Management Inc. now owns 3,615 shares of the biopharmaceutical company’s stock valued at $244,000 after buying an additional 165 shares during the last quarter. Finally, Perigon Wealth Management LLC grew its holdings in shares of Gilead Sciences by 0.3% during the second quarter. Perigon Wealth Management LLC now owns 51,335 shares of the biopharmaceutical company’s stock valued at $3,468,000 after buying an additional 165 shares during the last quarter. 79.91% of the stock is owned by institutional investors and hedge funds.

A number of research firms have recently commented on GILD. Wells Fargo & Co set a $81.00 price target on shares of Gilead Sciences and gave the company a “buy” rating in a report on Friday, October 25th. Jefferies Financial Group set a $95.00 price target on shares of Gilead Sciences and gave the company a “buy” rating in a report on Monday, July 15th. Robert W. Baird set a $76.00 target price on shares of Gilead Sciences and gave the stock a “hold” rating in a report on Friday, October 25th. Credit Suisse Group dropped their target price on shares of Gilead Sciences from $70.00 to $67.00 and set a “neutral” rating on the stock in a report on Wednesday, July 31st. Finally, BMO Capital Markets dropped their target price on shares of Gilead Sciences from $82.00 to $81.00 and set an “outperform” rating on the stock in a report on Friday, October 25th. One analyst has rated the stock with a sell rating, ten have issued a hold rating, fourteen have issued a buy rating and two have given a strong buy rating to the company. Gilead Sciences currently has an average rating of “Buy” and a consensus price target of $79.27.

NASDAQ GILD traded down $0.89 on Monday, reaching $64.49. The company had a trading volume of 242,334 shares, compared to its average volume of 6,639,518. The company has a quick ratio of 2.96, a current ratio of 3.06 and a debt-to-equity ratio of 1.13. The stock has a market capitalization of $82.81 billion, a PE ratio of 10.49, a price-to-earnings-growth ratio of 3.47 and a beta of 1.09. The firm’s 50 day moving average price is $64.15 and its 200 day moving average price is $65.25. Gilead Sciences, Inc. has a 12 month low of $60.32 and a 12 month high of $72.90.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, October 24th. The biopharmaceutical company reported $1.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.74 by $0.01. The company had revenue of $5.60 billion for the quarter, compared to the consensus estimate of $5.61 billion. Gilead Sciences had a net margin of 12.04% and a return on equity of 37.50%. Gilead Sciences’s revenue for the quarter was up .1% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.84 EPS. On average, research analysts expect that Gilead Sciences, Inc. will post 6.66 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Monday, December 30th. Shareholders of record on Friday, December 13th will be issued a $0.63 dividend. The ex-dividend date of this dividend is Thursday, December 12th. This represents a $2.52 dividend on an annualized basis and a yield of 3.91%. Gilead Sciences’s dividend payout ratio is currently 40.98%.

In related news, EVP Brett A. Pletcher sold 2,095 shares of Gilead Sciences stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $66.06, for a total transaction of $138,395.70. Following the completion of the transaction, the executive vice president now directly owns 17,826 shares of the company’s stock, valued at approximately $1,177,585.56. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Brett A. Pletcher sold 608 shares of Gilead Sciences stock in a transaction dated Monday, August 19th. The stock was sold at an average price of $64.35, for a total transaction of $39,124.80. Following the transaction, the executive vice president now directly owns 27,198 shares of the company’s stock, valued at $1,750,191.30. The disclosure for this sale can be found here. Over the last quarter, insiders sold 17,288 shares of company stock worth $1,108,682. 0.20% of the stock is currently owned by insiders.

About Gilead Sciences

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

Read More: After-Hours Trading

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.